• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line treatment patterns and overall survival in patients diagnosed with metastatic Merkel cell carcinoma in England from 2013 to 2020: results of a nationwide observational cohort study.

作者信息

Mahmoudpour Seyed Hamidreza, Knott Craig, Nobes Jenny, Kearney Mairead, Boutmy Emmanuelle, Verpillat Patrice, Venables Zoe C

机构信息

Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.

Health Data Insight CIC, NHS England, London, UK.

出版信息

Br J Dermatol. 2025 May 19;192(6):1134-1136. doi: 10.1093/bjd/ljaf063.

DOI:10.1093/bjd/ljaf063
PMID:40036636
Abstract
摘要

相似文献

1
First-line treatment patterns and overall survival in patients diagnosed with metastatic Merkel cell carcinoma in England from 2013 to 2020: results of a nationwide observational cohort study.2013年至2020年在英国被诊断为转移性默克尔细胞癌患者的一线治疗模式和总生存期：一项全国性观察性队列研究的结果
Br J Dermatol. 2025 May 19;192(6):1134-1136. doi: 10.1093/bjd/ljaf063.
2
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.在转移性 Merkel 细胞癌患者中进行一线avelumab 治疗：JAVELIN Merkel 200 研究 B 部分的 4 年随访结果。
ESMO Open. 2024 May;9(5):103461. doi: 10.1016/j.esmoop.2024.103461. Epub 2024 May 13.
3
Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.美国肿瘤临床实践中局部晚期或转移性 Merkel 细胞癌患者的真实世界临床结局：SPEAR-Merkel 研究结果。
Oncologist. 2021 Sep;26(9):e1633-e1643. doi: 10.1002/onco.13845. Epub 2021 Jul 2.
4
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.一线阿维鲁单抗治疗 IV 期转移性 Merkel 细胞癌患者的疗效和安全性：一项临床试验的预先计划的中期分析。
JAMA Oncol. 2018 Sep 1;4(9):e180077. doi: 10.1001/jamaoncol.2018.0077. Epub 2018 Sep 13.
5
Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.在美国，一线avelumab 治疗局部晚期/转移性 Merkel 细胞癌的真实世界临床结局：SPEAR-Merkel。
Future Oncol. 2021 Jun;17(18):2339-2350. doi: 10.2217/fon-2020-1250. Epub 2021 Mar 12.
6
Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.初治转移性默克尔细胞癌患者接受avelumab 治疗的体验：来自 JAVELIN Merkel 200 注册临床研究的纵向定性访谈结果。
Patient. 2020 Aug;13(4):457-467. doi: 10.1007/s40271-020-00428-5.
7
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.avelumab 一线治疗 116 例转移性 Merkel 细胞癌患者（JAVELIN Merkel 200 研究）：Ⅱ期研究的主要和生物标志物分析。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002646.
8
Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma.治疗初治和既往治疗转移性 Merkel 细胞癌患者时 FACT-M 问卷的心理计量学特性和最小有意义差异（MID）阈值的更新。
Health Qual Life Outcomes. 2020 May 19;18(1):145. doi: 10.1186/s12955-020-01402-3.
9
Epidemiology and survival of Merkel cell carcinoma in New Zealand: A population-based study between 2000 and 2015 with international comparison.新西兰 Merkel 细胞癌的流行病学和生存情况：2000 年至 2015 年的基于人群的研究及国际比较。
Australas J Dermatol. 2019 Nov;60(4):e284-e291. doi: 10.1111/ajd.13023. Epub 2019 Mar 21.
10
Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.美国新诊断默克尔细胞癌患者按化疗方案和合并症水平划分的治疗模式、合并症、医疗资源使用及相关成本
J Med Econ. 2018 Dec;21(12):1159-1171. doi: 10.1080/13696998.2018.1517089. Epub 2018 Sep 12.

引用本文的文献

1
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.通过靶向人类肿瘤外植体中的CD38克服免疫治疗耐药性。
Cell Rep Med. 2025 Jul 15;6(7):102210. doi: 10.1016/j.xcrm.2025.102210. Epub 2025 Jun 27.